ZD6126

ZD6126
Clinical data
Other names	ANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate
Identifiers
	IUPAC name Phosphoric acid mono-(5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl) ester;
CAS Number	219923-05-4 ;
PubChem CID	9896434;
ChemSpider	8072099 ;
UNII	GBO3S6M9W7;
CompTox Dashboard (EPA)	DTXSID20944593 ;
Chemical and physical data
Formula	C20H24NO8P
Molar mass	437.385 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC;
	InChI InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1 ; Key:UGBMEXLBFDAOGL-INIZCTEOSA-N ;
	(what is this?) (verify)

ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine. It has shown promising results on tumors in mice.

A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing. Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.

ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.